Meeting
2020 ASCO Virtual Scientific Program
Survival outcomes of patients with resectable pancreatic cancer treated with upfront surgery versus neoadjuvant chemotherapy: A retrospective tertiary care center experience.
Authors
Fang Liu
University Hospital, Cleveland, OH
Fang Liu , Matthew Mirsky , Sulin Wu , Pingfu Fu , Shufen Cao , John Shanahan , Ravi Kumar Kyasaram , Prantesh Jain , Jeffrey Hardacre , John Brian Ammori , Jordan Michael Winter , David Lawrence Bajor
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Track
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Sub Track
Pancreatic Cancer
Citation
J Clin Oncol 38: 2020 (suppl; abstr 4623)
DOI
10.1200/JCO.2020.38.15_suppl.4623
Abstract #
4623
Poster Bd #
231
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Gastrointestinal Cancers Symposium
A multi-institutional, single-arm, phase II trial of neoadjuvant modified-FOLFIRINOX for resectable pancreatic ductal adenocarcinoma.
First Author: Choong-kun Lee
Poster
2021 ASCO Annual Meeting
Total neoadjuvant FOLFIRINOX or gemcitabine-based chemoradiotherapy and adjuvant gemcitabine for resectable and borderline resectable pancreatic cancer (PREOPANC-2): A nationwide multicenter randomized controlled trial.
First Author: Quisette Janssen
Poster
2019 Gastrointestinal Cancers Symposium
Randomized phase II/III trial of neoadjuvant chemotherapy with gemcitabine and S-1 versus upfront surgery for resectable pancreatic cancer (Prep-02/JSAP-05).
First Author: Michiaki Unno
Poster
2019 Gastrointestinal Cancers Symposium
Comparison of neoadjuvant and adjuvant therapy for resectable pancreatic cancer using Markov decision modeling.
First Author: Minsig Choi